Related Experiment Video
Updated: Jan 11, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
Pazopanib in patients with primary multi-metastatic bone Ewing sarcoma
Anna Raciborska1, Katarzyna Bilska1, Jadwiga Węcławek-Tompol2
1Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland.
Frontiers in Oncology
|November 10, 2025
Summary
Pazopanib shows promise as a well-tolerated and effective treatment for young patients with multi-metastatic bone Ewing sarcoma, improving survival outcomes. Further investigation into this salvage regimen is warranted.
Area of Science:
- Pediatric Oncology
- Medical Oncology
- Sarcoma Research
Background:
- Primary multi-metastatic Ewing sarcoma in young patients has a poor prognosis despite various treatment regimens.
- Pazopanib, a tyrosine kinase inhibitor, has demonstrated efficacy in treating soft tissue sarcomas (STS), including extraosseous Ewing sarcoma (ESS).
- The study evaluates pazopanib as a potential salvage therapy for primary multi-metastatic bone Ewing sarcoma in pediatric patients.
Purpose of the Study:
- To assess the safety and efficacy of pazopanib in young patients with primary multi-metastatic bone Ewing sarcoma.
- To evaluate pazopanib's tolerability when administered concurrently with standard treatments like chemotherapy and radiation therapy.
- To determine the survival outcomes and toxicity profile of pazopanib in this patient population.
Main Methods:
- Eleven pediatric patients with primary multi-metastatic bone Ewing sarcoma received pazopanib alongside standard first-line treatments.
- Patients underwent regular tumor imaging and laboratory evaluations to monitor disease status and treatment response.
- Toxicities associated with pazopanib administration were meticulously documented throughout the study period.
Main Results:
- Pazopanib was well-tolerated in young patients, with no significant observed toxicities, even when combined with chemotherapy and radiation.
- The estimated 2-year event-free survival was 68.2%, and overall survival was 85.7%.
- Ten out of eleven patients (90.9%) remained alive at a median follow-up of 2.6 years, with only one progression and two relapses.
Conclusions:
- Pazopanib is a well-tolerated and effective treatment option for young patients with primary multi-metastatic Ewing sarcoma.
- The combination of pazopanib with standard therapies warrants further investigation for improved outcomes in this challenging disease.
- Pazopanib should be considered a viable salvage regimen for pediatric patients diagnosed with multi-metastatic bone Ewing sarcoma.
